Humblet, Yves

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 5,035

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 2,895

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 2,263

Open-Label Phase III Trial of Panitumumab plus Best Supportive Care Compared with Best Supportive Care Alone in Patients with Chemotherapy-Refractory Metastatic Colorectal Cancer

Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 1,979

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

De Roock, W., Piessevaux, H., De Schutter, J., Janssens, M., De Hertogh, G., Personeni, N., Biesmans, B., Van Laethem, J.-L., Peeters, M., Humblet, Y., et al. (2008) · Annals of Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 827

Final Results from PRIME: Randomized Phase III Study of Panitumumab with FOLFOX4 for First-Line Treatment of Metastatic Colorectal Cancer

Douillard, J. Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2014) · Annals of Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 606

Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.

Jacobs, B., De Roock, W., Piessevaux, H., Van Oirbeek, R., Biesmans, B., De Schutter, J., Fieuws, S., Vandesompele, J., Peeters, M., Van Laethem, J.-L., et al. (2009) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 368

Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer

Tabernero, J., Van Cutsem, E., Díaz-Rubio, E., Cervantes, A., Humblet, Y., André, T., Van Laethem, J.-L., Soulié, P., Casado, E., Verslype, C., et al. (2007) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 337

Aflibercept plus FOLFIRI vs. placebo plus FOLFIRI in second-line metastatic colorectal cancer: A post hoc analysis of survival from the phase III VELOUR study subsequent to exclusion of patients who had recurrence during or within 6 months of completing adjuvant oxaliplatin-based therapy

Van Cutsem, E., Joulain, F., Hoff, P. M., Mitchell, E., Ruff, P., Lakomý, R., Prausová, J., Moiseyenko, V. M., van Hazel, G., Cunningham, D., et al. (2016) · Targeted Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 49